Citrate Salts (Potassium Citrate, Sodium Citrate, Citric Acid)
Citrate salts are primarily utilized in veterinary medicine as **urinary alkalinizers** and in the management of **chronic metabolic acidosis**, a condition frequently associated with chronic kidney disease (CKD) or renal tubular acidosis. **Potassium citrate** is particularly valuable for the prevention of **calcium oxalate uroliths** (stones) in dogs and cats. It is often preferred over sodium bicarbonate because it is more palatable and provides potassium supplementation, which is beneficial since many CKD patients are prone to hypokalemia. *Clinical Pearl:* While highly effective for calcium oxalate prevention, overzealous alkalinization must be avoided, as a urine pH that is too high can inadvertently promote the formation of calcium phosphate uroliths.
Mechanism: Citrate salts are absorbed from the gastrointestinal tract and **oxidized in the liver** to produce **bicarbonate** (HCO3-), which acts as a systemic alkalinizing agent, raising blood pH and subsequently urine pH. In the urinary tract, the mechanism is twofold: 1. **Alkalinization**: The resulting alkaline urine increases the solubility of calcium oxalate. 2. **Chelation**: Excreted citrate directly **complexes with calcium** in the urine โ decreases the concentration of free calcium available to bind with oxalate โ inhibits the formation and growth of calcium oxalate crystals.
Dosing by species
- Adjunctive therapy to inhibit calcium oxalate formation ยท Initially 50-100 mg/kg PO q12h ยท PO ยท q12h ยท Goal is to achieve a urine pH of approximately 7.5.
- Decrease possibility of calcium oxalate stone formation (Nutrived Potassium Citrate Granules) ยท 1 scoop mixed or sprinkled on food per day ยท PO ยท q24h
- Adjunctive therapy to inhibit calcium oxalate formation ยท 100-150 mg/kg/day PO ยท PO ยท q24h ยท It is unclear whether this dose will actually increase urinary citrate in cats.
- Adjunctive therapy of chronic renal failure as a potassium supplement and alkalinizing agent ยท Initially, 75 mg/kg PO q12h ยท PO ยท q12h
- Significantly acidemic chronic renal failure ยท 2.5 mEq (total dose) potassium or 15-30 mg/kg as potassium citrate PO q12h ยท PO ยท q12h
- Hypokalemic chronic renal failure ยท 2-4 mEq (total dose) of potassium per day as potassium citrate or potassium gluconate ยท PO ยท q24h
- Adjunctive therapy to inhibit calcium oxalate crystal formation (hypocitraturia) ยท 40-75 mg/kg PO q12h ยท PO ยท q12h ยท Avoid overzealous urinary alkalinization as calcium phosphate uroliths may form.
- Adjunctive therapy to inhibit calcium oxalate crystal formation ยท Initially 50 mg/kg PO q12h ยท PO ยท q12h ยท Monitor urine pH; goal is to obtain values of 7-7.5.
- Decrease possibility of calcium oxalate stone formation (Nutrived Potassium Citrate Granules) ยท 1 scoop mixed or sprinkled on food per 10 lb. body weight per day ยท PO ยท q24h
Routes of administration
Contraindications
- Heart failure
- Severe renal impairment (with azotemia or oliguria)
- Urinary tract infections (UTI) associated with calcium or struvite stones
- Aluminum toxicity
- Hyperkalemia or conditions predisposing to it (adrenal insufficiency, acute dehydration, uncontrolled diabetes mellitus) - for potassium citrate
- Peptic ulcer disease
- Delayed gastric emptying, esophageal compression, or intestinal obstruction (specifically for tablet formulations)
Adverse effects
- Gastrointestinal distress (nausea, vomiting, diarrhea)
- Hyperkalemia (specifically with potassium citrate)
- Fluid retention (specifically with sodium citrate)
- Metabolic alkalosis (rare)
Drug interactions
- Amphetamines ยท Alkalinized urine can decrease excretion, potentially increasing toxicity.
- Pseudoephedrine / Ephedrine ยท Alkalinized urine can decrease excretion.
- Antacids ยท May cause systemic alkalosis. Aluminum-containing antacids may cause aluminum toxicity, especially in renal insufficiency. Sodium bicarbonate combinations may cause hypernatremia.
- Aspirin (Salicylates) ยท Alkalinized urine can increase the excretion of salicylates, decreasing their efficacy.
- Fluoroquinolones (e.g., ciprofloxacin, enrofloxacin) ยท Solubility is decreased in an alkaline environment; monitor for signs of crystalluria.
- Lithium ยท Alkalinized urine can decrease excretion.
- Methenamine ยท Concurrent use is not recommended as methenamine requires an acidic urine for efficacy.
- Quinidine ยท Alkalinized urine can decrease excretion.
- Tetracyclines ยท Alkalinized urine can decrease excretion.
- ACE Inhibitors (e.g., enalapril, lisinopril) ยท May lead to increases in serum potassium levels (hyperkalemia) when used with potassium citrate.
- Cyclosporine ยท May increase serum potassium levels when used with potassium citrate.
- Digoxin ยท May increase serum potassium levels when used with potassium citrate.
Monitoring
- Serum potassium, sodium, bicarbonate, chloride
- Acid/base status
- Urine pH
- Urinalysis (monitor for crystalluria)
- Serum creatinine and CBC (particularly in chronic renal failure)
Overdose
Overdosage and acute toxicity generally fall into 4 categories: 1. **Gastrointestinal distress and ulceration** 2. **Metabolic alkalosis** 3. **Hypernatremia** (with sodium citrate) 4. **Hyperkalemia** (with potassium citrate) **Treatment**: If an overdose occurs and preventing absorption is reasonable (especially with tablets), employ gut-emptying protocols if not contraindicated. Treat GI effects with intravenous fluids or supportive care. Hyperkalemia, hypernatremia, and metabolic alkalosis should be treated symptomatically. Contact an animal poison control center for specific treatment modalities.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturerโs current label.